GM1 ganglioside exerts protective effects against glutamate-excitotoxicity via its oligosaccharide in wild-type and amyotrophic lateral sclerosis motor neurons

FEBS Open Bio. 2023 Dec;13(12):2324-2341. doi: 10.1002/2211-5463.13727. Epub 2023 Nov 15.

Abstract

Alterations in glycosphingolipid metabolism have been linked to the pathophysiological mechanisms of amyotrophic lateral sclerosis (ALS), a neurodegenerative disease affecting motor neurons. Accordingly, administration of GM1, a sialic acid-containing glycosphingolipid, is protective against neuronal damage and supports neuronal homeostasis, with these effects mediated by its bioactive component, the oligosaccharide head (GM1-OS). Here, we add new evidence to the therapeutic efficacy of GM1 in ALS: Its administration to WT and SOD1G93A motor neurons affected by glutamate-induced excitotoxicity significantly increased neuronal survival and preserved neurite networks, counteracting intracellular protein accumulation and mitochondria impairment. Importantly, the GM1-OS faithfully replicates GM1 activity, emphasizing that even in ALS the protective function of GM1 strictly depends on its pentasaccharide.

Keywords: GM1 ganglioside; GM1 oligosaccharide; amyotrophic lateral sclerosis; excitotoxicity; intracellular aggregates; mitochondria.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amyotrophic Lateral Sclerosis* / drug therapy
  • Amyotrophic Lateral Sclerosis* / metabolism
  • G(M1) Ganglioside / metabolism
  • G(M1) Ganglioside / pharmacology
  • Glutamic Acid
  • Humans
  • Motor Neurons / metabolism
  • Neurodegenerative Diseases* / metabolism
  • Superoxide Dismutase / metabolism

Substances

  • G(M1) Ganglioside
  • Glutamic Acid
  • Superoxide Dismutase